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Abstract
Mitochondria are traditionally been viewed as the cell’s powerhouse, generating most of 
its ATP. However, besides this fundamental metabolic role, mitochondria are implicated in 
diverse other processes, including apoptosis, inflammation and metastasis. These functions 
are exerted in part by the growing class of long noncoding mitochondrial RNAs (lncmtRNAs). 
We found that normal human proliferating cells express a family of noncoding mitochon-
drial RNAs (ncmtRNAs), comprised of sense (SncmtRNA) and antisense (ASncmtRNA). 
However, tumor cells express only sense transcripts, suggesting that ASncmtRNA downreg-
ulation as a cancer new hallmark. The few ASncmtRNAs copies in tumor cells seem essen-
tial to tumor cell viability: knockdown of these transcripts with antisense oligonucleotides 
(ASO) causes massive apoptotic death of tumor cells, preceded by cell cycle arrest. Preclinical 
assays show that systemic administration of ASO delayed tumor growth in melanoma and 
renal cancer models and, caused total remission in subcutaneous renal cancer tumors. The 
same treatment, however, does not affect normal tissue, suggesting this approach for the 
development of an efficient and safe therapeutic strategy for several cancer types.
Keywords: cancer, mitochondria, long noncoding RNAs, antisense oligonucleotides, 
therapy
1. Introduction
Mitochondria are eukaryotic cell organelles that represent a universal system in higher organ-
isms which generate most of the cellular energy, in the form of ATP, necessary for different 
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cell processes. However, many other functions have been assigned to this tiny organelle, 
such as apoptosis, reactive oxidative species (ROS) signaling, inflammation and metastasis. 
Mitochondria play a central role in apoptosis, principally due to the release of proteins from the 
mitochondrial inter-membrane space [1], linking mitochondria to cell suicide. Mitochondria 
also represent a major source of DNA-damaging reactive oxygen species (ROS), mainly as by-
products of oxidative phosphorylation. In comparison to nuclear DNA, mitochondrial DNA 
(mtDNA) is more susceptible to DNA damage due to the reduced capacity of the cell to repair 
mtDNA, potentially promoting cancer [2].
In inflammation, mitochondria mainly serve as a source of various signaling molecules, termed 
damage-associated molecular patterns or DAMPS, which propagate inflammatory signals and 
therefore activate inflammation [3].
Cancer death is most often due to secondary tumors or metastasis. This process requires a 
complex series of events, which include epithelial-to-mesenchymal transition, stromal remod-
eling, invasion and ultimately migration of cancer cells. In this context, mitochondrial ROS 
play a key role, leading to angiogenesis and metastasis [4] and promoting the migratory plas-
ticity of cells through activation of two essential factors, Src and protein tyrosine kinase 2 [5]. 
The basic understanding of the dependence of cancer cells on various mitochondrial roles is 
already endorsing novel therapeutic approaches in cancer.
Along that line, an expanding group of evidences indicate that the mitochondrial genome is 
not only responsible for the synthesis of the canonical 13 proteins, 22 tRNAs and two ribo-
somal RNAs (12S and 16S). Novel and expanding evidence suggest that mtDNA compensates 
for reduced length by using little known phenomena that potentially increase DNA’s pro-
tein coding repertoire, such as so called swinger polymerization, that consists of systematic 
exchanges between nucleotides during DNA or RNA polymerization, producing so-called 
swinger sequences [6, 7]. These transformations alter gene and mRNA coding properties. 
Moreover, in human mitochondria systematic deletions of mono- and dinucleotides after 
each trinucleotide have been reported, producing delRNAs. Recently, an exhaustive analysis 
of human nanoLc mass spectrometry peptidome data detect numerous tetra- and pentapep-
tides translated from the human mitogenome, and this peptide subgroup would be the result 
of the translation of delRNAs. Therefore, non-canonical transcriptions and translations could 
considerably expand the coding potential of mitochondrial DNA and RNA sequences [8, 9].
Finally, in the field of antisense RNAs and because mitochondrial tRNA mutations are 6.5 times 
more frequently pathogenic than in other mitochondrial sequences, a potential additional tRNA 
gene function is that of templating for antisense tRNAs. Most antisense tRNAs probably function 
routinely in translation and extend the tRNA pool and mutation pathogenicity, probably fre-
quently resulting from a mixture of effects due to sense and antisense tRNA translational activity 
for many mitochondrial tRNAs [10, 11]. These could link to mitochondrial disorders and cancer.
This small but powerful organelle is also a novel source of noncoding RNAs (ncRNAs), and 
growing evidence shows that mammalian mitochondria can also import/export ncRNAs, 
turning this organelle into a pivotal player not only in cellular physiology but also in cancer, 
representing potential targets for innovative ncRNA-based treatment strategies [12].
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In this chapter we discuss the importance of long noncoding mitochondrial RNAs (lncmtRNAs) 
in diagnostic and pharmaceutical targeting in cancer.
2. Mitochondrial transcripts and noncoding RNAs
Human mitochondrial DNA (mtDNA) is a circular molecule of 16,569 bp in length [13] which 
encodes a small subset of 13 proteins required for OxPhos, 22 tRNAs and two ribosomal 
RNAs, 12S rRNA and 16S rRNA, which form part of the small (28S) and large (39S) subunits 
of the 55S mitoribosome [14]. All other protein components are encoded by nuclear genes and 
imported into mitochondria from the cytosol.
Replication and transcription of mtDNA is initiated from the D loop, a small noncoding region, 
and is regulated by nuclear-encoded proteins imported into mitochondria [15]. Mitochondrial 
RNAs are transcribed as long polycistronic precursors from both strands, termed heavy (H) 
and light (L) strands [16]. Except for NADH dehydrogenase 6 (ND6), all the 13-mitochondrial 
proteins are encoded in the H-strand. Additionally, the H-strand encodes 14 of the 22 tRNAs 
and the 2 rRNAs. The remaining 8 tRNAs are encoded on the L-strand [17]. The precursor 
transcripts are processed according to the tRNA punctuation model, whereby 22 interspersed 
tRNAs are excised at their 5’ and 3’ends by RNase P [18] and by RNase Z, elaC homology 
2 (ELAC2), respectively, releasing simultaneously individual rRNAs and mRNAs [19]. The 
RNAs then undergo maturation, involving polyadenilation at the 3’eextremitoess of mRNAs 
and rRNAs, and specific nucleotide modifications and addition of CCA trinucleotides to the 
3’eextremities of tRNAs [20]. The data of several groups indicate that 250–300 nuclear-encoded 
proteins are dedicated exclusively to serve mitochondrial gene expression. This includes RNA 
polymerase, endonucleases for RNA processing, translation factors, biogenesis factors for the 
mitochondrial ribosome, aminoacyl-tRNA synthetases, and other auxiliary factors [21, 22].
However, evidence has accumulated supporting the notion that, besides proteins, many types 
of RNAs transcribed from the nuclear genome are actively delivered to mitochondria. Among 
these transcripts are different types of noncoding RNAs, such as tRNAs, 5S rRNA, MRP RNA 
(RMRP) and RNase P RNA (RPPH1) [23], as well as microRNAs (mitomiRs) [24]. The logical 
explanation is that, despite their critical function, the handfuls of mitochondrial- and nuclear-
encoded proteins are insufficient to maintain mitochondrial structure or activity.
Noncoding RNAs (ncRNAs) are divided in two major groups according to size, as small non-
coding RNAs and long noncoding RNAs. Among the small ncRNAs, microRNAs (miRNAs) 
are the most-studied class in mammals. These RNAs (20–24 nucleotides in length) negatively 
regulate gene expression through binding with their target mRNA and have been implicated 
actively in pathogenic processes of many human diseases [24] and, as such, are important reg-
ulators of cancer cell metabolism [25]. The observation of association of miRNAs with/inside 
mitochondria may have important implications in several cellular processes and suggest that 
the role of mitochondria clearly extends beyond its role in energy metabolism and other cel-
lular processes. The newfound destination of miRNAs indicates novel roles of mitochondria 
in normal and pathological events [25].
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The class of long noncoding RNAs (lncRNAs) has been recently recognized, and is defined 
as transcripts longer than 200 nucleotides. The size cutoff is arbitrary and many functional 
lncRNAs are considerably longer than 200 nucleotides, including X-inactive specific tran-
script (XIST) [26], its antisense form Tsix [27], and Hox transcript antisense intergenic RNA 
(HOTAIR) [28], which are several kilobases (kb) in length.
LncRNAs are able to interact with DNA, RNA, and proteins. In doing so, they regulate sev-
eral processes including chromatin dynamics, gene transcription, splicing, and translation [29]. 
Their involvement in these processes implicates lncRNAs in various aspects of human physiol-
ogy and disease, which include cancer. Aberrant lncRNA expression has been associated to vari-
ous cancer types [30]. Moreover, deregulated lncRNA expression patterns can modulate several 
hallmarks of cancer [31], including sustained growth signaling, repressed growth inhibition, 
apoptosis evasion, stimulated proliferation, and the promotion of angiogenesis [32].
2.1. Long noncoding RNAs are generated in the mitochondria
Both strands of the mtDNA are entirely transcribed but the light strand carries only genes for 
seven tRNAs and the ND6 protein. Therefore, large noncoding sequences are thus generated 
and released upon transcript processing. Three lncRNAs generated from mtDNA transcrip-
tion have been proposed. Their presence was authenticated by Northern blot and qRT-PCR 
analysis. These transcripts are complementary to MTND5, MTND6 and MTCYTB genes. 
These molecules form intermolecular duplexes that resist RNase 1 digestion, suggesting regu-
lation of their complementary coding mRNA. Therefore, pairing of these lncRNAs with their 
mRNA targets might, for instance, control translation [33].
Recently, a novel mitochondrial long noncoding RNA (mtlncRNA) was identified in the 
plasma of patients with left ventricular (LV) remodeling post-myocardial infarction. Levels 
of LIPCAR (long intergenic noncoding RNA predicting cardiac remodeling) decline in early 
stages after myocardial infarction, but increase in late stages, coinciding with LV remodeling. 
Therefore, high levels of LIPCAR associate with identified patients with high risk of heart 
failure, even death, suggesting that this lncmtRNA as a potential biomarker for patients with 
recent episodes of acute myocardial infarction [34].
In the year 2000, our laboratory described a novel chimeric mitochondrial RNA present in mouse 
testis and sperm cells. This transcript contained an inverted repeat of 120nt joined to the 5′ end of 
the 16S mitochondrial rRNA. The presence of this novel mitochondrial RNA in sperm, testis, and 
somatic tissues was demonstrated by RT-PCR. As to the origin of this novel RNA, one possibility 
was that it arose from transcription altered mtDNA which contained an insert of 121bp between 
the tRNAVal and the 16S rRNA genes. However, PCR of sperm, testis, liver, and blood cell 
mtDNA between these two genes yielded a fragment of 342bp consistent with a normal mtDNA 
lacking the putative insertion of 121bp. The most surprising result was the localization of this 
novel RNA in the sperm nucleus. In situ hybridization (ISH) demonstrated that the sequence of 
the 16S rRNA and that of the inverted repeat were localized in the sperm nucleus [35].
Nuclear localization of this mitochondrial transcript is not specific to mouse since, by ISH, we 
found that at least the sequence of the 16S rRNA was also localized in the nucleus of human 
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sperm. To determine when during spermatogenesis the mitochondrial RNA is localized in 
the nucleus, ISH of mouse and human testis was carried out. The nuclei of spermatogonia, 
spermatocytes and round and elongated spermatids were all positively stained. In human 
spermatocytes, the nuclear staining pattern was fibrillar, suggesting an association of the 
mitochondrial transcript with the meiotic chromosomes [36].
These results suggested that the nuclear localization of the 16S mitochondrial rRNA in sper-
matogenic cells is the result of an intriguing process of translocation of the transcript from the 
organelle to the nucleus. This hypothesis leads to several important questions; for example, 
how does the organelle regulate the exit of the 16S mitochondrial rRNA without affecting the 
number of copies needed to assemble mitoribosomes for normal mitochondrial translation? 
Or what is the mechanism by which this RNA is exported from mitochondria? At present 
these questions remain unanswered.
However, the extramitochondrial localization of the 16S mitochondrial rRNA described by us is 
not unique, since the same transcript has been found consistently in the cytoplasm of Drosophila 
and Xenopus embryos [37, 38]. Moreover, injection of an anti-16S rRNA ribozyme into cleavage 
embryos of Drosophila demonstrated that the rRNA is actively involved in the generation of 
pole cells, progenitors of the germ line [39].
As mentioned above, ISH revealed that this lncRNA is over-expressed in human sperm and pre-
cursor cells [36]. These results suggest that human cells might contain a transcript with structural 
features similar to the mouse RNA. We found that the human RNA is over-expressed in sev-
eral human proliferating cells but not in resting cells. The structure of this transcript of 2374 nt, 
which we designated sense noncoding mitochondrial RNA or SncmtRNA, revealed the pres-
ence of an inverted repeat (IR) of 815 nt linked to the 5′ end of the 16S mtrRNA. The expression 
of this transcript can be induced in resting lymphocytes stimulated with phytohaemagglutinin 
(PHA), together with DNA synthesis and the expression of the proliferation markers proliferat-
ing cell nuclear antigen (PCNA), Ki-67 and phosphohistone H3. On the other hand, treatment of 
DU145 cells with aphidicolin reversibly blocks cell proliferation as well as the expression of the 
ncmtRNA. These results suggested that the ncmtRNA is a new marker of cell proliferation [40].
Afterwards, we described 2 mitochondrial transcripts (ASncmtRNAs) in human cells containing 
stem-loop structures similar to that of the previously described SncmtRNA. Regarding expression 
of the SncmtRNA and the ASncmtRNAs, 3 different phenotypes of human cells can be defined. 
Normal proliferating cells express both families of transcripts; in striking contrast, tumor cells 
express the SncmtRNA and down-regulate the ASncmtRNAs. Finally, neither of these transcripts 
is expressed in nondividing cells. Down-regulation of the ASncmtRNAs was observed in 15 differ-
ent tumor cell lines and in tumor cells present in 273 cancer biopsies corresponding to 17 different 
cancer types [41]. SncmtRNA is expressed in all proliferating cells, independently whether we are 
dealing with a regulated or a dysfunctional cell cycle. The fact that the ASncmtRNAs are always 
down-regulated in tumor cells suggests that, hypothetically, the ASncmtRNAs might function 
as a unique mitochondria-encoded tumor suppressor. Figure 1 shows a panel of ISH for S and 
ASncmtRNA in non-proliferating tissue (liver), tumor tissue (cervix carcinoma) and normal pro-
liferating tissue (normal cervix epithelium), representing the concept of differential expression 
mentioned. For in situ hybridization, tissue sections were incubated with hybridization mixture 
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containing probes complementary to sense or antisense ncmtRNAs, previously labeled at the 3′ 
end with digoxigenin-11-dUTP (Boehringer Mannheim, Germany) as described previously [36]. 
For detection, sections were incubated with a monoclonal anti-digoxigenin antibody conjugated 
to alkaline phosphatase, and after color development, positive signal correspond to a blue color, 
representing the expression of the corresponding RNA (see Figure 1).
Regarding subcellular localization, we found that in biopsies of normal and cancer tissues, 
nuclear localization of these transcripts was frequently observed. The extra-mitochondrial 
localization of these transcripts was confirmed by electron microscopy ISH. In normal cells, 
SncmtRNA and the ASncmtRNAs were found in the nucleus associated to chromatin. In 
tumor cells, SncmtRNA shows similar localization plus association with nucleoli, while the 
ASncmtRNAs are down-regulated. Although the meaning of the nuclear localization in normal 
proliferating cells of SncmtRNA and the ASncmtRNAs is unclear, the results suggest that these 
Figure 1. Representative in situ hybridization assay showing the differential expression pattern of lncmtRNAs in tissues 
according to proliferative status. Upper panel shows absence of signal for both RNAs in non-proliferating tissues such 
as liver. Middle panel shows presence of strong punctuate signal, corresponding to nuclei in normal proliferating 
cervix epithelium. Lower panel shows a strong signal corresponding only to SncmtRNA and complete absence of signal 
corresponding to ASncmtRNA in a tumor tissue, exemplified by cervix carcinoma. H&E, hematoxylin-eosin staining. 
Magnification in upper panel, ×200. Magnification in cervix tissues, ×100.
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transcripts might play a role in retrograde signaling. Down regulation of the ASncmtRNAs 
seems to be an important step in neoplastic transformation and cancer progression [42].
The study of RNA and DNA oncogenic viruses has proven valuable in the discovery of key 
cellular pathways that are rendered dysfunctional during cancer progression. Because of this, 
we studied human foreskin keratinocytes (HFK) immortalized with HPV in order to gain 
insight on the role of the lncmtRNAs in cell proliferation. We showed that immortalization of 
HFK with HPV-16 or 18 causes downregulation of the ASncmtRNAs and induces the expres-
sion of a new sense transcript termed SncmtRNA-2.
Transduction of HFK with both E6 and E7 oncoproteins is sufficient to induce expression 
of SncmtRNA-2. On the other hand, the E2 oncogene is involved in downregulation of the 
ASncmtRNAs. Knockdown of E2 in immortalized cells reestablishes in a reversible manner 
the expression of the ASncmtRNAs, suggesting that endogenous cellular factors(s) could play 
functions analogous to E2 during non-viral-induced oncogenesis [43]. Our results suggest that 
a fraction of SncmtRNA-1 is processed outside of the organelle, to give rise to SncmtRNA-2 and 
a 63-nt fragment released from the IR. In silico analysis of this sequence revealed that the 63-nt 
fragment is highly complementary to hsa-miR-620. Using the TargetScan algorithm (www.tar-
getscan.com), we found >100 predictive targets for hsa-miR-620 [44]. An interesting example 
is the mRNA of promyelocytic leukemia (PML) protein, which is a core component of PML 
nuclear bodies found in tumor cells, important structures involved in HPV replication. Several 
reports indicate that the E6 and E7 oncoproteins are localized in these nuclear structures [45].
2.2. Differential expression of lncmtRNAs as a tool for cancer diagnostics
As mentioned above, the ASncmtRNAs are downregulated in tumor cell lines and cells in 
tumor biopsies, independently of the tissular origin of the tumor analyzed. Therefore, this 
differential expression might be used for screening of cancer cells.
Cervical cancer is the fourth most common cancer in women worldwide. In 2012, this disease 
accounted for 528,000 new cases and 266,000 deaths among females [46]. Cervical cancer is of 
slow progression and, according to histopathological studies, there are at least three well-defined 
stages preceding cervical squamous carcinoma, known as cervical intraepithelial neoplasia 
(CIN). These stages (CIN1, CIN2 and CIN3) correspond to the progressive invasion of the cervi-
cal epithelium from the basal cell layer to the surface of the squamous epithelium [47]. Therefore, 
detection of premalignant lesions is key to preventing disease progression to advanced stages.
Therefore, we performed a study in order to evaluate and quantify the differential expres-
sion of non-coding mitochondrial RNAs during the progression of the disease. We found 
down-regulation of the antisense mitochondrial transcripts at early stages of cervical neo-
plasia (CIN1). Moreover, differential expression of ASncmtRNA v/s S-ncmtRNA showed 
significant difference, while, as expected, normal proliferating tissues did not display down-
regulation of ASncmtRNAs. Moreover, downregulation of ASncmtRNAs correlated with the 
over-expression of the tumor suppressor protein p16INK-4a [48, 49].
Bladder cancer (BC) is a significant cause of morbidity and mortality with a high recurrence 
rate. Early detection of bladder cancer is essential in order to remove the tumor, to preserve 
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the organ and to avoid metastasis. The “gold standard” in the detection of BC is cystoscopy. 
This examination, however, is unpleasant, time consuming, expensive and may result in infec-
tions and urethral damage [50]. In a pilot study, we analyzed the differential expression of 
SncmtRNA and ASncmtRNAs in cells isolated from voided urine from patients with bladder 
cancer as a noninvasive diagnostic assay. For this purpose, we developed a test based on a 
multiprobe mixture labeled with different fluorophores, which takes about 1 hour to complete. 
We examined the expression of these transcripts in cells isolated from urine of 24 patients with 
BC and 15 healthy donors. The samples from BC patients revealed expression of SncmtRNA 
and downregulation of the ASncmtRNAs. Exfoliated cells recovered from the urine of healthy 
donors did not express these mitochondrial transcripts. The differential expression of the 
SncmtRNA and the ASncmtRNAs in cells isolated from voided urine can be explored as a new 
non-invasive diagnostic test for bladder cancer [51].
2.3. Targeting antisense noncoding mitochondrial RNA: From bench to clinic
As mentioned before, we postulated that the ASncmtRNAs might function as a unique 
mitochondria-encoded tumor suppressor. Therefore, we tested whether ASncmtRNA knock-
down (ASK for short) induces alteration of cancer cell function. We found, in several tumor 
cell lines, that knockdown of the low copy number of the ASncmtRNAs with antisense oli-
gonucleotides (ASO) induces massive cancer cell death by apoptosis without affecting the 
viability of normal cells. Apoptosis is triggered or potentiated by a drastic reduction in lev-
els of survivin, a member of the inhibitor of apoptosis (IAP) family that is overexpressed 
in virtually all human cancers. Down-regulation of survivin is at the post-transcriptional 
level and probably mediated by microRNAs generated by Dicer from the ASncmtRNAs after 
ASO-induced RNase H processing [52]. It is important to highlight that the ASO treatment is 
efficient in inducing knockdown of the ASncmtRNAs, despite the fact that it is well known 
that oligonucleotides are not able to enter mitochondria in vivo [53]. In consequence, the 
obvious question is how are these transcripts targeted by ASOs? We have demonstrated that 
in normal human kidneys, renal cell carcinoma, mouse testis and the murine melanoma cell 
line B16F10, SncmtRNA and the ASncmtRNAs exit the mitochondria and are found local-
ized in the cytoplasm and in the nucleus [42]. Consequently, our results suggest that the 
functional role of these molecules lies outside the organelle. Besides cell viability, ASK also 
drastically reduces proliferative index, anchorage-independent growth capacity, migration 
and invasion [52]. Taken together, our results allow us to propose that downregulation of the 
ASncmtRNAs constitutes an Achilles’ heel of cancer cells, suggesting that the ASncmtRNAs 
are promising targets for cancer therapy.
In consequence, the ultimate challenge is to translate these results to an in vivo preclinical 
scenario with immunocompetent mice. For this purpose, we first characterized the murine 
noncoding mitochondrial RNAs (mncmtRNAs), which display structures similar to the human 
counterparts, including long double-stranded regions arising from the presence of inverted 
repeats. Most remarkable however is the identical expression pattern of these transcripts in 
both species. The mASncmtRNAs, expressed in normal proliferating cells, are downregulated 
in mouse tumor cells. ASK with ASO targeted to the mASncmtRNAs induces apoptotic cell 
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death of the highly aggressive and metastatic murine melanoma cell line B16F10 in vitro, con-
comitantly with survivin downregulation [54].
We assessed the efficacy of the ASO treatment in vivo, using a B16F10 syngeneic model in 
C57BL6/J, where we applied a therapeutic approach similar to the clinical practice guidelines of 
melanoma: surgical resection of the lesion followed by systemic administration of ASO targeted 
to mASncmtRNAs (1560S). Remarkably, there was no visible sign of lung or liver metastasis 
at 120 days since the beginning of treatment with ASO, although one cannot discard the pos-
sibility of micro-metastasis [54]. In tail vein injection lung colonization assay, ASO treatment 
significantly reduced the number of metastatic nodules in the lungs, as well as their size [54]. 
Similar results were obtained in this model with a lentiviral delivery approach of therapeutic 
sequences. Transduction with lentiviral constructs targeted to the ASncmtRNAs induced apop-
tosis in murine B16F10 and human A375 melanoma cells in vitro and significantly retarded 
B16F10 primary tumor growth in vivo. ASK treatment drastically reduced the number of lung 
metastatic foci in a tail vein injection assay, compared to controls [55]. These results provide 
additional proof-of-concept for knockdown of ncmtRNAs for cancer therapy and altogether, 
our results suggest that ASncmtRNAs could be potent targets for melanoma therapy.
In the RenCa cell line, corresponding to murine renal adenocarcinoma, we showed that ASK 
in vitro induces apoptosis mediated by downregulation of survivin, Bcl-2 and BclxL, the lat-
ter 2 members of another family of anti-apoptotic factors [56]. ASK also induces detrimen-
tal effects on metastatic potential, such as downregulation of N-cadherin, P-cadherin and 
MMP9, further strengthening the potential of this strategy for renal cell carcinoma (RCC) 
therapy. Remarkably, our in vivo studies in a subcutaneous syngeneic model of RenCa cells 
in Balb/C mice show complete reversal of tumor growth [57]. Moreover, in an orthotopic 
assay of murine RCC induced by injection of RenCa cells into the subcapsular region of the 
kidney showed that all the control mice contained tumors of different size. In contrast, only 
one mouse treated with the therapeutic ASO exhibited a small tumor. Histological analysis of 
each lung showed that control mice contained several and large metastatic nodules. In con-
trast, only two lungs of mice treated with therapeutical ASO contained metastatic nodules, 
which were significantly fewer and smaller. Finally, direct metastasis assessment by tail vein 
injection of RenCa cells also showed a drastic reduction in lung metastatic nodules [57].
These pre-clinical results with the RenCa and B16F10 murine models establish proof-of-concept 
that the ASncmtRNAs constitute a potent and selective target to develop a treatment for differ-
ent types of cancer and positions this approach as an attractive strategy ready for clinical testing.
In this respect, the USA Food and Drug Administration (FDA) approved an oligonucleotide 
directed to the human ASncmtRNAs Andes-1537) as IND for a Phase I Clinical Trial. This study, 
currently under way and close to completion at UCSF, California, USA, is a first-in-human, 
open-label, dose escalation and expansion, 2-part study to determine the safety, tolerability, and 
maximum tolerated dose of Andes-1537 for Injection in patients with advanced unresectable 
solid tumors that are refractory to standard therapy or for which no standard therapy is avail-
able (NCT02508441). The result of this trial will be very important in order to continue with the 
next phase to assess the antitumoral efficacy of this therapy in human cancer patients.
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3. Conclusions
Downregulation of the ASncmtRNAs has been assessed in several tumor tissues, such as blad-
der, prostate, kidney, ovary, cervix and breast, among others [58]. The role of these transcripts 
in cell proliferation and tumorigenesis is not fully understood at present. However, down-
regulation of the ASncmtRNAs while maintaining the expression of SncmtRNA represents 
a universal characteristic of tumor cells. The strong inhibition of tumor growth, induction of 
apoptosis and even tumor remission after knockdown of these RNAs in vivo is an impressive 
phenomenon that constitutes a unique opportunity for the development of a targeted therapy 
against several types of cancer. Moreover, the fact that antisense therapy does not cause side 
effects constitutes an attribute not observed in other kinds of therapies and opens the door to 
the evaluation of this approach in different kinds of solid tumors.
The mechanism by which interference of these RNAs generates cell death, apoptosis and 
delay in metastasis is beyond the scope of this review. However, our preliminary evidence 
indicates that the double strand region of the antisense RNAs is a seed for generation of 
miRNAs, which could target mRNAs of several proteins involved in cell cycle control, cell 
survival, invasion and metastasis. Therefore, knockdown of these RNAs generates a pleiotro-
pic effect that affects simultaneously several important pathways necessary throughout the 
whole tumorigenic process.
Mitochondrial long noncoding RNAs are novel actors in cancer metabolism and understand-
ing the roles they fulfill in tumor cell biology will make it possible to select in the future novel 
targets for the development of new therapies that could be effective and of low toxicity for 
patients. Our target described here meets these two requirements and at present is being 
evaluated in a Phase I protocol soon to finish. Those results will give the necessary data to 
continue with the next phase and to evaluate more in depth the efficacy of our therapy.
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